Allium CE marks prostatic stent
This article was originally published in Clinica
Executive Summary
Allium Group has CE marked its prostatic stent for sale in Europe. Used in patients with benign prostatic hyperplasia (BPH) or with advanced prostate cancer, the device has a triangular cross-section to match the contours of the prostatic urethra, and can exert varying degrees of radial force depending on the anatomy and function of the part of the urethra in which it is deployed. This means the device is more comfortable than existing stents in the long term, the Caesarea, Israel firm said. Distribution of the stent will begin during the first months of 2009.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.